
Novel Drug Targets for Treatment of...
Evotec and Indivumed achieve Milestone in joint strategic Drug Discovery Collaboration
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced today that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer.











